What Is Happening With Mesoblast Shares?

Mesoblast shares (ASX:MSB) were the worst performer on the ASX 200 on Friday, falling back 7.14% to A$2.21, to sit 20.22% down YTD. With the MSB share price having been trading 6.73% higher last week leading into Friday’s pullback, this was a swift and sharp reversal. So what happened?

The Filing

State Street Corporation’s disclosure that it now holds 5.1% of Mesoblast was one potential trigger the Friday selloff, but the devil lay in the details. The substantial holder notice revealed that the position is largely attributable to stock-borrowing and securities-lending programmes rather than a conventional long-term investment stake. Transaction schedules accompanying the ASX filing showed multiple entries labelled “Borrow – for stock borrows” and “Lend – for stock lend”, indicating State Street’s role as a custodian and lending intermediary rather than an active stock picker making a high-conviction bet.

ASX securities-lending data separately shows Mesoblast recording lending volumes of approximately 14-15% of total trading volume in recent reports, placing it among the more actively borrowed stocks on the exchange. This intensity of lending activity is particularly pronounced in the biotech sector, where binary clinical and regulatory outcomes create natural demand for both long and short positioning.

State Street, as a major global custodian managing trillions in assets through index funds and ETFs, routinely lends securities from its custody accounts to generate additional returns. However, the market’s reaction to the notice suggests traders interpreted the disclosure as evidence of growing capacity for short sellers rather than a neutral flow event.

Markets quickly connected the dots between the State Street filing and the potential for increased short selling pressure. When a substantial holder notice reveals that a large position is tied to securities lending rather than fundamental conviction, traders typically interpret this as bearish for near-term price action. The logic follows that more stock available to borrow means shorts can more easily build or maintain positions, creating a technical overhang that can suppress rallies and amplify selloffs.

Outlook and What Comes Next

The State Street notice itself does not alter Mesoblast’s underlying science, clinical pipeline, or regulatory trajectory. For bulls, the current setup presents a classic biotech risk-reward profile, where elevated short interest and negative technical momentum create the conditions for explosive upside if a strong positive catalyst materialises. Any announcement of regulatory approval, a major partnership, or better-than-expected clinical data could force shorts to cover rapidly.

Bears, meanwhile, point to the lending data as evidence that smart money remains sceptical. The fact that recent rallies have been met with selling pressure, and that securities-lending volumes remain elevated, suggests the path of least resistance for the share price is sideways to lower in the absence of concrete positive developments. Capital-raising risk also looms for pre-revenue biotechs, with shorts often positioning ahead of perceived funding gaps.

The fundamental backdrop has not shifted substantially on the week, yet the perception that selling pressure may be on the horizon has led to some front running the potential move. Whether it materialises or not is another matter entirely. Time will tell.